Will brand pharma take advantage of its new opportunity?
The work pharmaceutical brands have done to overcome an inherent scepticism toward them must be nurtured and built on
Read More
Search Results for: Barry Silverstein
- Cambridge researchers develop robotic nerve devices for neurological conditions
- International phase 3 clinical trial for new melanoma treatment recruits first patients
- Nova’s Xromi approved in UK and EU for vaso-occlusive complications of SCD
- Study reveals vitamin D-altered mouse gut bacteria provides better cancer immunity
- Cambridge researchers use AI to accelerate drug design for Parkinson’s disease
